Prostate cancer treatment
AssigneeGalderma S.A.
InventorAndy PICKETT
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination of botulinum toxin and hyaluronic acid for use in the radiation treatment of cancer. The present invention also relates to a method for treating prostate cancer in a human patient, whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved and the rectum is protected from a subsequent radiation treatment step. Furthermore, the present invention relates to one or more compounds selected from botulinum toxin, hyaluronic acid and a combination of botulinum toxin and hyaluronic acid for use in the treatment of prostate cancer in a human patient by a method whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved and the rectum is protected from a subsequent radiation treatment step.
Claims12
1-8. (canceled)
A method for treating prostate cancer in a human patient, comprising:
- a) administering a first composition comprising a therapeutically active amount of a botulinum toxin to a prostate of said patient,
- b) allowing the botulinum toxin to act on one or more tumours in the prostate, whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved,
- c) administering a second composition comprising hyaluronic acid to a location between the prostate and rectum of said patient to protect the rectum from a subsequent radiation treatment step d,
- d) exposing the prostate of said patient to radiation therapy, whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved.
A method for treating prostate cancer in a human patient, comprising administering a combination of botulinum toxin and hyaluronic acid to a prostrate of said patient.
A kit for use in radiation treatment of prostate cancer, the kit comprising a first composition comprising a botulinum toxin and a second composition comprising hyaluronic acid, wherein the first composition and second composition are different, wherein the first composition and the second composition are configured for use in the radiation treatment of prostate cancer in a human patient.
Dependencies are inferred from the claim text.